We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 20, 2022

Personalized Response-Directed Surgery and Adjuvant Therapy After Neoadjuvant Ipilimumab and Nivolumab in High-Risk Stage III Melanoma

Nature Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Nat. Med. 2022 Jun 05;[EPub Ahead of Print], ILM Reijers, AM Menzies, ACJ van Akkooi, JM Versluis, NMJ van den Heuvel, RPM Saw, TE Pennington, E Kapiteijn, AAM van der Veldt, KPM Suijkerbuijk, GAP Hospers, EA Rozeman, WMC Klop, WJ van Houdt, K Sikorska, JA van der Hage, DJ Grünhagen, MW Wouters, AJ Witkamp, CL Zuur, JM Lijnsvelt, A Torres Acosta, LG Grijpink-Ongering, M Gonzalez, K Jóźwiak, C Bierman, KF Shannon, S Ch'ng, AJ Colebatch, AJ Spillane, JBAG Haanen, RV Rawson, BA van de Wiel, LV van de Poll-Franse, RA Scolyer, AH Boekhout, GV Long, CU Blank

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading